English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

For PET imaging of mantle cell lymphoma (MCL), [ 18 F]FDG (2-deoxy-2-[ 18 F]fluoro-D-glucose) is the currently recommended radiotracer, although uptake is variable and bone marrow evaluation is limited. In this prospective study, we evaluated the novel CXCR4 (G-protein-coupled C-X-C chemokine receptor type 4) tracer [ 68 Ga]Pentixafor in MCL patients, and compared it to [ 18 F]FDG. Methods: MCL patients underwent [ 68 Ga]Pentixafor-PET/MRI, and, if required for routine purposes, also [ 18 F]FDG-PET/MRI, before treatment. PET was evaluated separately for 23 anatomic regions (12 lymph node stations and 11 organs/tissues), using MRI as the main reference standard. Standardized uptake values (SUV max and SUV mean ) and tumor-to-background ratios (TBR blood and TBR liver ) were calculated. General Estimation Equations (GEE) were used to compare [ 68 Ga]Pentixafor-PET and [ 18 F]FDG-PET sensitivities and positive predictive values (PPV). For bone marrow involvement, where biopsy served as the main reference standard, and splenic involvement, receiver operating characteristic curves were used to determine the optimal SUV and TBR cut-off values, and areas under the curve (AUC) were calculated. Results: Twenty-two MCL patients were included. [ 68 Ga]Pentixafor-PET sensitivity (100%) was significantly higher than for [ 18 F]FDG-PET (75.2%) ( P &lt;0.001), and PPV was slightly, but not significantly lower (94.0%.vs. 96.5%; P =0.21). SUVs and TBRs were significantly higher for [ 68 Ga]Pentixafor-PET than for [ 18 F]FDG-PET ( P &lt;0.001 in all cases); the greatest difference was observed for mean TBR blood , with 4.9 for [ 68 Ga]Pentixafor-PET and 2.0 for [ 18 F]FDG-PET. For bone marrow involvement, [ 68 Ga]Pentixafor-PET SUV mean showed an AUC of 0.92; and for splenic involvement, TBR blood showed an AUC of 0.81. Conclusion: [ 68 Ga]Pentixafor-PET may become an alternative to [ 18 F]FDG-PET in MCL patients, showing clearly higher detection rates and better tumor-to-background contrast.

CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET

CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸Ga]Pentixafor: comparison with [¹⁸F]FDG-PET